References
- Meakins J L, Christou N V, Shizgal H M. Therapeutic approaches to anergy in surgical patients. Ann Surg 1979; 190: 286–296
- Calhoun K, Trachtenberg L, Hart M A. Corynebacterium parvum: Immunomodulation in local bacterial infections. Surgery 1980; 87: 52–57
- Fagelman K M, Flint L M, McCoy M T. Simulated surgical wound infection in mice. Arch Surg 1981; 116: 761–764
- Ellouz F, Adam A, Ciorbaru R. Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivatives. Biochem Biophys Res Commun 1974; 6: 1317–1325
- Chedid L, Audibert F, Johnson A G. Biological activities of murarnyl dipeptide, a synthetic glyccpeptide analogous to bacterial immunoregulating agents. Prog Allergy 1978; 25: 63–105
- Chedid L, Parant M, Parant F. Enhancement of nonspecific immunity of Klebsiella pneumonia infection by a synthetic immunoadjuvant (N-acetyl-muramyl-L-alanyl-D-isoglutamine) and several analogs. Proc Natl Acad Sci USA 1977; 74: 2089–2093
- Lamont P M, Schrodt G R, Galland R B. Enhancement of the local inflammatory response to bacterial infection by muramyl dipeptide. Br J Exp Pathol 1984; 65: 319–325
- Galland R B, Trachtenberg L S, Rynerson N. Nonspecific enhancement of resistance to local bacterial infection in starved mice. Arch Surg 1982; 117: 161–164
- Polk HC, Jr, Galland R B, Ausobsky J R. Nonspecific enhancement of resistance to bacterial infection: Evidence of an effect supplemental to antibiotics. Ann Surg 1982; 196: 436–441
- Ausobsky J R, Scuitto M, Trachtenberg L S. The role of muramyl dipeptide in the therapy of established experimental infection. Br J Exp Pathol 1984; 55: 1–9
- Rosenblum M G, Hortobagyi G N, Wingender W. Analysis of the antitumor agent BAY i 7433 (copovithane) in plasma and urine by high performance liquid chromatography. J Liq Chromatog 1984; 7: 159–166
- Schlumberger H D. BAY i 7433: A synthetic polymer with anti-tumor activity. Augmenting Agents in Cancer Therapy, E M Hersh, M A Chirigos, MJ Mastrangelo. Raven Press, New York 1983; 373–390
- Hortobagyi G, Frye D, Papadopoulos N. Phase I clinical trial of copovithane (CPV), a new antitumor agent. Proc 74. Annals of the Meeting of the American Association of Cancer Research 1983; 24: 145–A572
- Moffat F L, Clark A G, Falk M. Enhanced survival in antibiotic-treated murine fecal peritonitis by administration of copovithane, a selective immuno-stimulative polymer. J Surg Res 1985; 38: 494–500
- Moffat F L, Falk R E, Teodorczyk-Injeyan J. Reversal of cyclosporin-induced mortality with a synthetic polymeric immunostimulant in a murine mdel of fecal peritonitis. Transplantation 1985; 39: 369–374
- Fevrier M, Birrien J L, LeClerc C. The macrophage, target cell of the synthetic adjuvant muramyl dipeptide. Eur J Immunol 1978; 8: 558–562
- McCoy D M, Brown G L, Ausobsky J R. Muramyl dipeptide enhances in vitro peritoneal macrophage phagocytic capacity. Am Surg 1983; 51: 634–636
- Masihi K N, Ozel M, Lange W. Lipophilic muramyl dipeptide-induced changes in electron microscopic morphology and phagocytic function of murine macrophages. J Biol Response Mod 1986; 5: 20–26